MedCity Pivot Podcast: A Conversation with Lumen CEO Daniel Tal Mor
In this episode, the CEO of Lumen talks about the sleek consumer device and why he is at a b-to-b healthcare conference.
4 digital health trends for 2022
Funding for digital health is blowing up, and the sky’s the limit for a healthcare world suddenly, and solidly, committed to tech innovations. Here’s what we can expect to see more of next year.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
23andMe to buy online pharmacy Lemonaid for $400M
The company plans to pair its direct-to-consumer genetic testing with Lemonaid’s online coaching and prescription delivery. It plans to buy the company for $400 million in stock and cash.
Sesame adds online pharmacy to cash-pay marketplace
The startup, where patients access cash-pay telehealth and in-person visits, recently added prescription delivery through Truepill. It’s offering a list of generic medications for $5.
D2C in healthcare: Why now is the perfect time
Opportunities exist in many areas of the industry, and patients are hungrier than ever for more engaging and humane experiences. For D2C brands that are ready to capitalize on the changing market, the sky's the limit.
Sidestepping the system – Is D2C the next winning model in healthcare?
While D2C can enable creativity in customer acquisition and B2B strategies allow for rapid monetization, companies must thoughtfully target consumers, track clinical outcomes, and demonstrate cost-savings.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Strategies that will help make 2021 a banner year for life sciences industries
Covid-19 showed that pharma companies can be nimble and implement changes that prevent processes from weighing down on operations. But which of these operational and strategic changes will stand the test of time and make this year and the future bright for the industry?
After $1.6B blank-check deal, Hims & Hers plots expansion into more conditions
The three-year-old digital health startup began trading on the New York Stock Exchange on Thursday. It merged with a subsidiary of Oaktree Capital Management in a deal that valued the company at $1.6 billion.
Optum Ventures co-founder launches digital health platform for LGBTQ patients
A.G. Breitenstein, a founding partner with Optum Ventures, launched FOLX on Thursday. The direct-to-consumer health platform is designed specifically with LGBTQ patients in mind.
Eargo goes public, raising $141.3M
The Bay Area hearing device-maker planned to raise $141.3 million in an upsized IPO. Its stock started trading on Nasdaq under the ticker “EAR.”
Maximize Revenue and Patient Care with Strategic Weight Loss Management
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Hims & Hers to go public through blank-check company
The direct-to-consumer telehealth startup will go public through a merger with special purpose acquisition company Oaktree Acquisition Corp. The combined entity is expected to be valued at $1.6 billion.
Telehealth startup brings gender-affirming care to employee benefits programs
Plume provides access to telehealth consultations for patients seeking gender-affirming hormone therapy. Recently, the startup began partnering with employers to offer its services as a benefit.
Truepill turns to in-home lab testing with $75M in new funding
Truepill, the startup behind direct-to-consumer health brands like Hims and Nurx, plans to expand into lab testing. The startup raised $75 million in a series C funding round.
Direct-to-consumer health company Thirty Madison raises $47M
Thirty Madison, which operates three brands for hair loss, migraines and acid reflux, raised $47 million in a series B round. Polaris Partners led the round, and Johnson & Johnson participated as an investor.
Dental company SmileDirectClub files to go public
The company offers personalized 3-D printed clear aligners - essentially a form of transparent plastic braces - in a direct to consumer model that it touts as cheaper and more convenient than traditional options.